Trial
NCT07369791
Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer.
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
National Health Research Institutes, Taiwan
Collaborators
—
Condition
Advanced Biliary Tract Cancer(BTC)
Intervention
Nivolumab
Why stopped
The study was terminated due to administrative reasons following the cancellation of collaboration between the involved parties.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-07-02